Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | XBP1 | P17861 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977690 | 1.00 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL31236338 | 0.88 | MAPT (0.77) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL5142590 | 0.88 | MAPT (0.77) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL9843030 | 0.88 | HDAC3 (0.68) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL5167203 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL9429509 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL30212894 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL693942 | 0.85 | MAPT (0.72) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL693941 | 0.85 | MAPT (0.72) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL26627751 | 0.85 | MAPT (0.72) | SMN1; SMN2MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573898-B | Treat and prevent hepatitis b virus infected new pyridazinone and triazinone | 豪夫迈·罗氏有限公司 | 2018-11-09 | — | — | CN | claimed |
| CN-106573898-A | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2017-04-19 | — | — | CN | claimed |
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | ADIONICS (FR) | 2026-05-12 | — | — | US | disclosed |
| CN-113292128-B | Apparatus and method for desalting water by thermal deionization and liquid phase ion extraction | 艾迪奥尼克斯公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230382775-A1 | METHOD FOR EXTRACTING SALTS AND TEMPERATURE-REGENERATED EXTRACTING COMPOSITION | ADIONICS (FR) | 2023-11-30 | — | — | US | disclosed |
| US-11772997-B2 | Method for extracting salts and temperature-regenerated extracting composition | ADIONICS (FR) | 2023-10-03 | — | — | US | disclosed |
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | ADIONICS (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-109641160-B | Method for extracting salt and temperature-regenerated extraction composition | 艾迪奥尼克斯公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3247677-B1 | LIQUID ORGANIC COMPOSITION FOR ION EXTRACTION IN LIQUID PHASE | ADIONICS (FR) | 2021-12-08 | — | — | EP | disclosed |
| US-20210355076-A1 | DEVICE AND METHOD FOR THE DESALINATION OF WATER BY MEANS OF THERMAL DEIONISATION AND LIQUID-PHASE ION EXTRACTION LIQUID | ADIONICS (FR) | 2021-11-18 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-7875707-B2 | combinatorial libraries; lipid solubility; solid phase synthesis | ALCHEMIA LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-1156044-B1 | 6-SUBSTITUTED HETEROQUINOLINECARBOXYLIC ACID DERIVATIVES AND ADDITION SALTS THEREOF AND PROCESSES FOR THE PREPARATION OF BOTH | KYORIN SEIYAKU KK (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-6562839-B1 | Effective for the therapy of disorder of cerebral nerve cells as antagonists against excitatory amino acid receptors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1156044-A1 | 6-SUBSTITUTED HETEROQUINOLINECARBOXYLIC ACID DERIVATIVES AND ADDITION SALTS THEREOF AND PROCESSES FOR THE PREPARATION OF BOTH | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | AQP3, AQP1, AQP4 | SMN1; SMN2 2006/4885MAPT 3644/4885MEN1 4431/4885 |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | SMN1; SMN2 1966/4885MAPT 3741/4885MEN1 4208/4885 |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | SMN1; SMN2 479/4885MAPT 2212/4885MEN1 3500/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | SMN1; SMN2 1572/4885MAPT 3034/4885MEN1 3895/4885 |
| US-20210355076-A1 | DEVICE AND METHOD FOR THE DESALINATION OF WATER BY MEANS OF THERMAL DEIONISATION AND LIQUID-PHASE ION EXTRACTION LIQUID | AQP3, AQP1, AQP4 | SMN1; SMN2 2006/4885MAPT 3644/4885MEN1 4431/4885 |
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | POLQ, NONO, AQP3 | SMN1; SMN2 1046/4885MAPT 3057/4885MEN1 4052/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | SMN1; SMN2 500/4885MAPT 2380/4885MEN1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.